ECCO 2022

Novel Treatment Modalities

Guselkumab shows encouraging safety and efficacy in ulcerative colitis

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 2, QUASAR Induction

Conference

ECCO 2022

12 April, 2022 16:23

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, GALAXI-1

Conference

ECCO 2022

12 April, 2022 16:21

Mirikizumab efficacious for active ulcerative colitis

Presented By

Prof. Geert D’Haens, Amsterdam University Medical Center, the Netherlands

Trial

Phase 3, LUCENT-1

Conference

ECCO 2022

12 April, 2022 16:18

Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Presented By

Dr Peter Bossuyt, Imelda General Hospital, Belgium

Trial

Phase 3, ADVANCE, MOTIVATE, FORTIFY

Conference

ECCO 2022

12 April, 2022 16:15

Guselkumab plus golimumab promising combination for ulcerative colitis

Presented By

Prof. Bruce Sands, Mount Sinai School of Medicine, NY, USA

Trial

Phase 2, VEGA

Conference

ECCO 2022

12 April, 2022 16:10

Combined endpoint may support personalised medicine in ulcerative colitis

Presented By

Prof. Stefan Schreiber, Christian-Albrecht University, Germany

Trial

Phase 3, SELECTION

Conference

ECCO 2022

12 April, 2022 16:06

Filgotinib seems promising for perianal fistulising Crohn’s disease

Presented By

Dr Walter Reinisch, Medical University of Vienna, Austria

Trial

Phase 2, DIVERGENCE 2

Conference

ECCO 2022

12 April, 2022 16:04

Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, U-ACHIEVE

Conference

ECCO 2022

12 April, 2022 15:57

Upadacitinib counters extraintestinal manifestations in ulcerative colitis

Presented By

Prof. Jean-Frédéric Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, U-ACHIEVE; U-ACCOMPLISH

Conference

ECCO 2022

12 April, 2022 15:53

Upadacitinib effector pathways unravelled

Presented By

Dr Bram Verstockt, KU Leuven, Belgium

Trial

Phase 2, U-ACHIEVE

Conference

ECCO 2022

12 April, 2022 15:49

Deucravacitinib does not meet primary endpoint for ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, LATTICE-UC

Conference

ECCO 2022

12 April, 2022 15:43

Head-to-Head Comparisons

Short-Term and Long-Term Treatment Results

Ozanimod treatment shows maintained response in ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, True North

Conference

ECCO 2022

12 April, 2022 16:57

Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease

Presented By

Prof. Edouard Louis, University Hospital Liège, Belgium

Trial

Phase 4, SPARE

Conference

ECCO 2022

12 April, 2022 16:55

Vedolizumab first approved therapy for chronic pouchitis

Presented By

Prof. Simon Travis, University of Oxford, UK

Trial

Phase 4, EARNEST

Conference

ECCO 2022

12 April, 2022 16:53

VEDOKIDS: Vedolizumab seems effective in paediatric IBD

Presented By

Dr Dan Turner, Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Israel

Trial

VEDOKIDS

Conference

ECCO 2022

12 April, 2022 16:51

Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met

Presented By

Dr Marie Truyens, Ghent University Hospital, Belgium

Trial

Phase 2, Trp-IBD

Conference

ECCO 2022

12 April, 2022 16:48

Specific Therapeutic Strategies

Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy

Presented By

Dr Kristin Jørgensen, Akershus University Hospital, Norway

Trial

NOR-DRUM B

Conference

ECCO 2022

12 April, 2022 17:14

Segmental colectomy beneficial over total colectomy in Chrohn’s disease

Presented By

Dr Gianluca Pellino, University of Campania Luigi Vanvitelli, Italy

Trial

SCOTCH

Conference

ECCO 2022

12 April, 2022 17:11

Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative

Presented By

Dr Stefan Holubar, Cleveland Clinic Foundation, OH, USA

Conference

ECCO 2022

12 April, 2022 17:06

Similar results for different corticosteroid tapering protocols in UC

Presented By

Ms Pernille Ovesen, Herlev University Hospital, Denmark

Trial

SCOTCH

Conference

ECCO 2022

12 April, 2022 17:04

Miscellaneous Topics

Lessons from the COVID-19 pandemic for IBD management

Presented By

Prof. Siew Ng, Chinese University of Hong Kong, Hong Kong

Conference

ECCO 2022

12 April, 2022 17:32

AI model distinguishes between histologic activity and remission in ulcerative colitis

Presented By

Dr Tommaso Parigi, Humanitas University, Italy

Trial

PICaSSO

Conference

ECCO 2022

12 April, 2022 17:29

Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors

Presented By

Dr Yael Haberman, Sheba Medical Center, Israel

Conference

ECCO 2022

12 April, 2022 17:27

Novel classification system for perianal fistulising Crohn’s disease

Presented By

Dr Philip Tozer, St Mark’s Hospital and Academic Institute, UK

Conference

ECCO 2022

12 April, 2022 17:26

Vaccination tool associated with improved vaccination coverage in IBD

Presented By

Ms Liselotte Fierens, KU Leuven, Belgium

Conference

ECCO 2022

12 April, 2022 17:24

Comparable safety profiles of biological therapies in elderly patients with IBD

Presented By

Dr Gustavo Drügg Hahn, McGill University Health Center, Canada

Conference

ECCO 2022

12 April, 2022 17:22

Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease

Presented By

Prof. Shomron Ben-Horin, Tel-Aviv University, Israel

Conference

ECCO 2022

12 April, 2022 17:21

RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools

Presented By

Dr Clara Caenepeel, KU Leuven, Belgium

Trial

RESTORE-UC

Conference

ECCO 2022

12 April, 2022 17:17